|
Published: November 13, 2020
Four out of five patients with heart failure are eligible for treatment with an SGLT2 inhibitor
American Heart Association’s Scientific Sessions 2020 – Presentation P2397
This link is provided for convenience only and is not an endorsement of either the linked-to entity or any product or service.
